The commission doesn’t require its members to divest their own personal biotech investments — even as they help shape U.S. policy overseeing the industry.
Schmidt holds stakes in several biotech companies through a venture capital firm known as First Spark Ventures.
The former Google CEO is in a position to potentially profit if those companies are the beneficiaries of a new wave of federal biotech spending.
